2023
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells
Brina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D’Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Rüschoff J, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J, Alimonti A. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nature Cancer 2023, 4: 1102-1121. PMID: 37460872, PMCID: PMC11331482, DOI: 10.1038/s43018-023-00594-z.Peer-Reviewed Original ResearchConceptsMyeloid-derived suppressor cellsProstate cancerAvailable immunotherapiesSuppressive myeloid cellsAKT inhibitor ipatasertibAkt/mTORProstate tumor cellsDifferent genetic alterationsMDSC infiltrationSuppressor cellsImmune surveillanceMDSC migrationTherapeutic strategiesMyeloid cellsTumor growthImmunotherapyCancerTumor cellsMNK1/2 inhibitorGenetic alterationsHGFSPP1Translational levelCellsCoordinated loss
2022
MODL-22. Establishment of a novel system to specifically trace and ablate quiescent/slow cycling cells in high-grade glioma
Antonica F, Santomaso L, Pernici D, Petrucci L, Aiello G, Cutarelli A, Conti L, Romanel A, Miele E, Tebaldi T, Tiberi L. MODL-22. Establishment of a novel system to specifically trace and ablate quiescent/slow cycling cells in high-grade glioma. Neuro-Oncology 2022, 24: i173-i173. DOI: 10.1093/neuonc/noac079.645.Peer-Reviewed Original ResearchSlow-cycling cellsHigh-grade gliomasBrain cancerCancer organoidsTumor infiltrationHigh-grade brain cancerAdult high-grade gliomasTumor cellsHigh-grade glioma patientsCommon malignant brain tumorCycling tumor cellsPediatric high-grade glioma patientsMalignant brain tumorsSlow cycling stem cellsCycling cellsHuman tumor samplesPoor prognosisSurgical removalMalignant featuresTumor relapseGlioma patientsMouse modelBrain tumorsTemozolomide treatmentMalignant cells